Lucy Wray: UK Investor 2017 the biggest & most exciting yet - Great reasons to book NOW for April 21 2018!
New General Election Caption Contest: A bearded, terrorist loving, commie lunatic we all despise - and the other man is Gerry Adams
General Election Caption Contest Winner: UKIP's Paul Nutter confirms he is standing in General Election edition
Hayward Tyler – Takeover Panel extension, loan repayment can again kicked slightly further down the road
Published 2 days ago
AIM-listed Advanced Oncotherapy (AVO) has announced this morning the drawdown of the second tranche of £1.3 million (nominal - £1.235 million after the 5% discount) on its convertible loan note (aka death spiral) package with Bracknor. Good news – the lights will stay on for a few weeks extra. But the second half of the statement is a bit of a puzzle, raising more questions than it seemingly tries to answer.
Published 3 days ago
Well that explains it then! Yesterday I noted my amazement that AIM-listed Advanced Oncotherapy (AVO) had issued yet another ramparoonie director share purchase RNS on Tuesday and that the shares had raced back above not only the all-important 27.5p mark, but above 30p. Now we know why: Executive Chairman Dr Michael Sinclair was in the market filling his boots with 200,000 shares at an average price of 30.44p. Shame he didn’t pile in when the shares were hovering around the 26p mark so as to save himself a few quid.
Published 4 days ago
At no-one-is-watching o’clock last night (5.48 pm) AIM-listed Advanced Oncotherapy (AVO) slipped out an announcement that it had drawn the £2m second tranche of cash available under its one-year loan deal with Blackfinch. With my maths suggesting that the company was close to running on fumes that extra £2m to keep the show on the road pro tem will come in handy.
Published 10 days ago
As shares in AIM-listed Advanced Oncotherapy (AVO) again sit below that all-important 27.5p mark which, if continued for 10 trading days, will trigger a EGM to reduce the nominal value of the company’s shares, a quick trip to the Companies House website reveals the debenture paperwork (HERE) related to the company’s recently announced loan deal (with spoof 100p conversion terms) with Blackfinch as announced on 27 March (HERE). Most of it is legalese, but on page 36 we get some cracking tit-bits. Such as the planned expenditure on the Harley Street premises (some £19.14 million) as against potential resale values of between £9.44 million and £10.71 million – and that is just for the kit and fitting, not for the value of the property itself. As security (including the property) for a £3 million loan (with an option for a further £2 million) it is quite something!